Riskpilot← Back to searchSign inGet full accessOPTIPHARMA AS
ASActiveOrg 995227371Hestehagen 2, 1448 DrøbakManufacture of other food products n.e.c. · NACE 1089Est. 20107 employees
Revenue 2024
NOK 34,4M
+7% vs 2023
EBITDA margin
48.4%
+30% vs 2023
Equity ratio
13.4%
Financial strength
Net profit 2024
NOK 13,2M
+34% vs 2023
| Revenue | NOK 34,4M | +7% |
| EBITDA | NOK 16,6M | +30% |
| Net profit | NOK 13,2M | +34% |
| Total assets | NOK 22,3M | +11% |
| Equity | NOK 3M | +95% |
| Employees | 7 | — |
Legal name
OPTIPHARMA AS
Org number
995227371
Legal form
Aksjeselskap
NACE code
1089 · Manufacture of other food products n.e.c.
Founded
27. februar 2010
Share capital
NOK 100 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utvikling, produksjon og handel med produkter innen helsekost, kosmetikk og beslektede områder, samt invetseringer innenfor disse områdene.
Address
Hestehagen 2, 1448 Drøbak
Phone
+4799741300
Email
anders@optipharma.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 15 021 | 22 482 | 23 991 | 32 034 | 34 386 |
| Staff expenses | −2 552 | −2 565 | −3 901 | −3 924 | −3 937 |
| EBITDA | 5 105 | 9 309 | 9 925 | 12 797 | 16 629 |
| Depreciation & amort. | −200 | −434 | −374 | −325 | −204 |
| EBIT | 4 905 | 8 875 | 9 551 | 12 472 | 16 425 |
| Net financials | −42 | 24 | −69 | 105 | 445 |
| Profit before tax | 4 864 | 8 899 | 9 482 | 12 577 | 16 870 |
| Tax | 1 070 | 1 958 | 2 087 | 2 767 | 3 716 |
| Net profit | 3 794 | 6 941 | 7 395 | 9 810 | 13 155 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 8 981 | 10 956 | 15 141 | 20 104 | 22 282 |
| Equity | 1 158 | 3 098 | 3 524 | 1 534 | 2 989 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 7 824 | 7 857 | 11 617 | 18 569 | 19 293 |
| Total debt | 7 824 | 7 857 | 11 617 | 18 569 | 19 293 |
EBITDA margin
48.4%
This company
15.8%
Market median
+206% vs market
20202024
Equity ratio
13.4%
This company
38.2%
Market median
-65% vs market
20202024
Return on equity
440.1%
This company
18.4%
Market median
+2292% vs market
20202024
Net profit margin
38.3%
This company
8.1%
Market median
+373% vs market
20202024
Asset turnover
1.54×
This company
1.12×
Market median
+37% vs market
20202024
Debt / equity
6.45×
This company
0.62×
Market median
-940% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LF Deputy Member | Deputy Member | 2025 |
| Former (1) | ||
MY Deputy Member | Deputy Member | 2012 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2012 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rubus As
OPTIPHARMA AS Board members of OPTIPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mari Ytterdal Høgli | Deputy Member | 0 companies |
| Lars Fredrik Gullhagen Revling | Deputy Member | 0 companies |
| Anders Krogsrud | Chairman | 0 companies |